Evolent Health, Inc.

NYSE:EVH

Medical - Healthcare Information Services

Healthcare
$3.93 -6.00%

-$0.28 today

Market cap
$442.05M
Beta
0.83
P/E (TTM)
-1.0
EPS (TTM)
-$4.44
52W Low $2.10High $12.07

Volume 3.10M

Average 2.78M

EVH Sales of Investments

Cash received from selling or redeeming investments.

Evolent Health, Inc.NYSE: EVH

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments outflow grows to $0

Q1 FY2026 sales of investments was $0, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $986K. Over 3 fiscal years it compounded at -43.8% a year.

Context

  • Sales of investments amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $246.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$986K+13985.7% YoY
LTMMar 2026
$986K+13985.7% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+13985.7%——
3-year CAGR-43.8%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
986K USD
Year-over-year change
+13985.7%
4-year CAGR
+18.5%

Sales of Investments vs competitors

How EVH compares with its peers on the latest reported figures

  • EVH's LTM Mar 2026 sales of investments of $986K is the 8th largest of the 11 companies compared; the peer median is $14.59M.
  • Its year-over-year change of +13985.7% is the highest of 8, against a peer median of -19.2%.
  • Sales of investments amounts to 0.1% of revenue for EVH, versus a peer median of 0.2%.
EVH Competitors Peer median
Sales of Investments for EVH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REPLReplimune Group, Inc.LTM Dec 2025$367.56M -19.2%+14.7%—
KURAKura Oncology, Inc.LTM Mar 2026$325M -37.3%+35.4%453.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$223.03M +378.2%——
PSNLPersonalis, Inc.LTM Mar 2026$171.96M +77.7%-5.0%266.5%
HSTMHealthStream, Inc.LTM Mar 2026$23.17M -18.0%—7.4%
AMNAMN Healthcare Services, Inc.LTM Mar 2026$6.02M -60.8%-9.2%0.2%
NUTXNutex Health, Inc.LTM Mar 2026$1.35M ——0.2%
EVHEvolent Health, Inc.LTM Mar 2026$986K +13985.7%-43.8%0.1%
BFLYButterfly Network, Inc.LTM Mar 2026$0 ——0.0%
MGTXMeiraGTx Holdings plcLTM Mar 2026$0 ——0.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding EVH) $14.59M-19.2%+4.9%0.2%

Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(37.6M)(19.16M)(113.04M)(61.62M)(579.4M)
Depreciation & Amortization60.04M67.2M123.42M125.62M122.65M
Deferred Income Tax(526K)342K(31.27M)(2.82M)(2.98M)
Stock-Based Compensation16.71M33.98M40.5M39.75M39.74M
Change in Working Capital(22.49M)(104.44M)21.89M(116.56M)(57.38M)
Accounts Receivables(24.76M)(102.98M)(164.69M)32.06M73.7M
Inventory00000
Accounts Payables7.25M13.17M(6.72M)4.25M6.64M
Other Working Capital(4.98M)(14.63M)193.31M(152.87M)(137.73M)
Other Non-Cash Items22.62M10.53M101.09M34.4M516.23M
Operating Cash Flow38.75M(11.55M)142.58M18.77M38.84M
Capital Expenditures(24.98M)(38.36M)(28.75M)(24.89M)(34.09M)
Acquisitions (Net)14.22M5.55M870K(30.73M)(57.44M)
Purchases of Investments(3M)(5.55M)0(7.32M)(1M)
Sales of Investments500K5.55M07K986K
Other Investing Activities(2.53M)(226.31M)(387.67M)091.31M
Investing Cash Flow(15.79M)(259.12M)(415.54M)(62.93M)(233K)
Debt Repayment(37.69M)219.74M183.29M58.58M65.06M
Common Stock Issued13.29M4.45M180.52M3.46M0
Common Stock Repurchased0000(40M)
Dividends Paid(1.3M)(14.88M)(18.79M)(20.09M)(11.13M)
Other Financing Activities(3.85M)(77.77M)(63.68M)(42.52M)(49.86M)
Financing Cash Flow(29.55M)131.54M281.34M(565K)(35.92M)
Effect of Forex Changes(52K)(657K)(79K)(229K)11.81M
Net Change in Cash(6.64M)(139.78M)8.3M(44.96M)14.49M
Free Cash Flow13.76M(49.91M)113.84M(6.13M)4.76M

Evolent Health, Inc.

NYSE:EVH

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.